At the recent World Professional Association for Transgender Health (WPATH) 28th Scientific Symposium, “A Gender Diverse World in Global Unity,” Joshua Safer, MD, FACP, FACE, Executive Director of the Mount Sinai Center for Transgender Medicine and Surgery, and others from Mount Sinai presented leading-edge research on hormone therapy for transgender and gender-diverse patients.
This presentation was one of 17 delivered by the Mount Sinai team, showcasing their commitment to advancing knowledge and promoting access, equity, and inclusion in health care.
The symposium, held from September 25-30 in Lisbon, Portugal, brought together medical experts, advocates, students, and colleagues from around the world to share insights and collaborate on advancing transgender and gender-diverse health care.
Mount Sinai’s Center for Transgender Medicine and Surgery, alongside the Office for Diversity and Inclusion, played a key role in the symposium and hosted a reception that allowed participants to network and discuss important research, highlights, and best practices in the field.
Dr. Safer was a panelist in a discussion of adjunct agents, or additional therapies, used with estrogens for feminizing hormone therapy in transgender women. In addition, Daniel J. Slack, MD, Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease), presented important data suggesting that blood clots in transgender women might be connected to other medical conditions and health care access issues rather than the estrogen therapy that is often blamed.
Presentations by the Mount Sinai team also included substantial data regarding the benefits of specific gender-affirming surgical techniques and opportunities to address health care gaps for transgender people.
Together, we are pushing the boundaries of research and championing the health and well-being of all,” Dr. Safer says. “We look forward to continuing this vital work and building a future where everyone can thrive.”